Current Report Filing (8-k)
January 07 2019 - 8:39AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 7, 2019
Heron Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-33221
|
|
94-2875566
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
4242 Campus Point Court, Suite 200, San Diego, CA
|
|
92121
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code (858)
251-4400
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On January 7, 2019, Heron Therapeutics, Inc. (the Company) issued a press release announcing, among other things, certain of its financial
results for the three and twelve months ended December 31, 2018 (the Press Release). A copy of the Press Release is furnished herewith as Exhibit 99.1.
This Item 2.02 and the Press Release attached hereto as Exhibit 99.1 are being furnished to the Securities and Exchange Commission.
Item 7.01 Regulation FD Disclosure.
Press
Release.
On January 7, 2019, the Company issued the Press Release providing, among other things, a general update on corporate progress, as
described in the Press Release.
Corporate Presentation.
A copy of presentation materials describing the business of the Company, all or a part of which may be used by the Company in investor or scientific
presentations from time to time, is furnished herewith as Exhibit 99.2 (the Corporate Presentation). The Corporate Presentation has also been posted on the Companys website at
www.herontx.com
. The Company does
not undertake any obligation to update the Corporate Presentation.
This Item 7.01, the Press Release and the Corporate Presentation are being furnished
to the Securities and Exchange Commission.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
Heron Therapeutics, Inc.
|
|
|
|
|
Date: January 7, 2019
|
|
|
|
|
|
/s/ David L. Szekeres
|
|
|
|
|
|
|
David L. Szekeres
|
|
|
|
|
|
|
Senior Vice President, General Counsel,
Business Development and Corporate Secretary
|
Heron Therapeautics (NASDAQ:HRTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Heron Therapeautics (NASDAQ:HRTX)
Historical Stock Chart
From Sep 2023 to Sep 2024